The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis

Seminars in Immunology

Volumn 21, Issue 5, 2009, Pages 308-312

  Engel, David ^a   Seijkens, Tom ^a   Poggi, Marjorie ^a   Sanati, Maryam ^b   Thevissen, Larissa ^b   Beckers, Linda ^a   Wijnands, Erwin ^a   Lievens, Dirk ^a   Lutgens, Esther ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Atherosclerosis; CD154; CD40; Co stimulation; Inflammation

Indexed keywords

APOLIPOPROTEIN E; B7 ANTIGEN; CD11B ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN RECEPTOR; M 158; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AORTA ATHEROSCLEROSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM;

ANIMALS; ANTIGENS, CD40; ATHEROSCLEROSIS; CD40 LIGAND; HUMANS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 70349157633     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2009.06.004     Document Type: Review

References (57)

1. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6 (2006) 508-519
2. Virmani R., Kolodgie F.D., Burke A.P., Farb A., and Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 (2000) 1262-1275
3. Weber C., Zernecke A., and Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8 (2008) 802-815
4. Galkina E., and Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27 (2009) 165-197
5. Kuiper J., van Puijvelde G.H., van Wanrooij E.J., van Es T., Habets K., Hauer A.D., et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol 18 (2007) 521-526
6. Kim W.J., Kang Y.J., Suk K., Park J.E., Kwon B.S., and Lee W.H. Comparative analysis of the expression patterns of various TNFSF/TNFRSF in atherosclerotic plaques. Immunol Invest 37 (2008) 359-373
7. de Boer O.J., Hirsch F., van der Wal A.C., van der Loos C.M., Das P.K., and Becker A.E. Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis 133 (1997) 227-234
8. Gotsman I., Sharpe A.H., and Lichtman A.H. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 103 (2008) 1220-1231
9. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
10. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat Rev Immunol 3 (2003) 609-620
11. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9 (2009) 271-285
12. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23 (2005) 23-68
13. Buono C., Pang H., Uchida Y., Libby P., Sharpe A.H., and Lichtman A.H. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 109 (2004) 2009-2015
14. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12 (2006) 178-180
15. Afek A., Harats D., Roth A., Keren G., and George J. A functional role for inducible costimulator (ICOS) in atherosclerosis. Atherosclerosis 183 (2005) 57-63
16. Gotsman I., Grabie N., Gupta R., Dacosta R., MacConmara M., Lederer J., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114 (2006) 2047-2055
17. Gotsman I., Grabie N., Dacosta R., Sukhova G., Sharpe A., and Lichtman A.H. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 117 (2007) 2974-2982
18. Wang X., Ria M., Kelmenson P.M., Eriksson P., Higgins D.C., Samnegard A., et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 37 (2005) 365-372
19. van Wanrooij E.J., van Puijvelde G.H., de Vos P., Yagita H., van Berkel T.J., and Kuiper J. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 204-210
20. Olofsson P.S., Soderstrom L.A., Wagsater D., Sheikine Y., Ocaya P., Lang F., et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117 (2008) 1292-1301
21. Lutgens E., Lievens D., Beckers L., Donners M., and Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 17 (2007) 118-123
22. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16 (1998) 111-135
23. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
24. Lutgens E., and Daemen M.J. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12 (2002) 27-32
25. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., and Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
26. Lutgens E., Gorelik L., Daemen M.J., de Muinck E.D., Grewal I.S., Koteliansky V.E., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 5 (1999) 1313-1316
27. Lutgens E., Cleutjens K.B., Heeneman S., Koteliansky V.E., Burkly L.C., and Daemen M.J. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 97 (2000) 7464-7469
28. Schonbeck U., Sukhova G.K., Shimizu K., Mach F., and Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 97 (2000) 7458-7463
29. Smook M.L., Heeringa P., Damoiseaux J.G., Daemen M.J., de Winther M.P., Gijbels M.J., et al. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 183 (2005) 275-282
30. Bavendiek U., Zirlik A., LaClair S., MacFarlane L., Libby P., and Schonbeck U. Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol 25 (2005) 1244-1249
31. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., and Noelle R.J. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 14 (1996) 591-617
32. Garlichs C.D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
33. Kopp C.W., Steiner S., Nasel C., Seidinger D., Mlekusch I., Lang W., et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke 34 (2003) 2560-2567
34. Sanguigni V., Pignatelli P., Lenti L., Ferro D., Bellia A., Carnevale R., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111 (2005) 412-419
35. Cipollone F., Chiarelli F., Davi G., Ferri C., Desideri G., Fazia M., et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 48 (2005) 1216-1224
36. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
37. Cipollone F., Ferri C., Desideri G., Paloscia L., Materazzo G., Mascellanti M., et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 108 (2003) 2776-2782
38. Zirlik A., Maier C., Gerdes N., MacFarlane L., Soosairajah J., Bavendiek U., et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 115 (2007) 1571-1580
39. Donners M.M., Beckers L., Lievens D., Munnix I., Heemskerk J., Janssen B.J., et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 111 (2008) 4596-4604
40. Wagner A.H., Guldenzoph B., Lienenluke B., and Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 24 (2004) 715-720
41. Mach F., Schonbeck U., Bonnefoy J.Y., Pober J.S., and Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96 (1997) 396-399
42. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
43. van Gils J.M., Zwaginga J.J., and Hordijk P.L. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 85 (2009) 195-204
44. Li G., Sanders J.M., Bevard M.H., Sun Z., Chumley J.W., Galkina E.V., et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 172 (2008) 1141-1152
45. Mach F., Schonbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.Y., Pober J.S., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94 (1997) 1931-1936
46. Bavendiek U., Libby P., Kilbride M., Reynolds R., Mackman N., and Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 277 (2002) 25032-25039
47. Schonbeck U., Mach F., Sukhova G.K., Herman M., Graber P., Kehry M.R., et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 156 (2000) 7-14
48. Andre P., Prasad K.S., Denis C.V., He M., Papalia J.M., Hynes R.O., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8 (2002) 247-252
49. Kawai T., Andrews D., Colvin R.B., Sachs D.H., and Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6 (2000) 114
50. Zapata J.M. TNF-receptor-associated factors as targets for drug development. Expert Opin Ther Targets 7 (2003) 411-425
51. Arron J.R., Pewzner-Jung Y., Walsh M.C., Kobayashi T., and Choi Y. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp Med 196 (2002) 923-934
52. Ishida T.K., Tojo T., Aoki T., Kobayashi N., Ohishi T., Watanabe T., et al. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 93 (1996) 9437-9442
53. Lu L.F., Ahonen C.L., Lind E.F., Raman V.S., Cook W.J., Lin L.L., et al. The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation. Blood 110 (2007) 193-200
54. Ahonen C., Manning E., Erickson L.D., O'Connor B., Lind E.F., Pullen S.S., et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol 3 (2002) 451-456
55. Mukundan L., Bishop G.A., Head K.Z., Zhang L., Wahl L.M., and Suttles J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol 174 (2005) 1081-1090
56. Mukundan L., Milhorn D.M., Matta B., and Suttles J. CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway. Cell Signal 16 (2004) 375-384
57. Urbich C., Mallat Z., Tedgui A., Clauss M., Zeiher A.M., and Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest 108 (2001) 1451-1458